调强放疗同步替吉奥或卡培他滨化疗治疗中老年晚期食管癌的临床研究  

Clinical research of intensity modulated radiotherapy combined with S-1 or capecitabine chemotherapy in the treatment of middle-aged and elderly patients with advanced esophageal cancer

作　　者：杜峰 王光明 魏曾曾[2] Du Feng;Wang Guangming;Wei Zengzeng(Department of Tumor Radiotherapy,Fuyang Cancer Hospital of Anhui Province,Anhui Fuyang 236000,China;General Medicine,Second Affiliated Hospital of Anhui Medical University,Anhui Hefei 230601,China)

机构地区：[1]安徽省阜阳市肿瘤医院放疗科,安徽阜阳236000 [2]安徽医科大学第二附属医院全科医学科,安徽合肥230601

出　　处：《中国医刊》2022年第4期389-392,共4页Chinese Journal of Medicine

摘　　要：目的比较调强放疗同步替吉奥或卡培他滨化疗在中老年晚期食管癌治疗中的临床疗效。方法回顾性分析2017年4月至2020年10月安徽省阜阳市肿瘤医院收治的50例中老年晚期食管癌患者的临床资料,根据治疗方法不同将研究对象分为调强放疗同步替吉奥化疗组(放疗+替吉奥组,25例)和调强放疗同步卡培他滨化疗组(放疗+卡培他滨组,25例)。21d为1个周期,两组患者均治疗2个周期。比较分析两组患者治疗结束后的临床疗效,治疗后1年的不良反应发生情况以及治疗后4个月、6个月、12个月的生存情况。结果治疗结束后,放疗+替吉奥组患者的总缓解率显著高于放疗+卡培他滨组(P<0.05)。治疗后1年,两组患者的骨髓抑制和消化道不良反应发生率比较差异均无显著性(P>0.05);放疗+替吉奥组患者的末梢神经炎、放射性食管炎、手足皮肤损伤发生率均显著低于放疗+卡培他滨组(P<0.05)。治疗后4个月,两组患者的生存率比较差异无显著性(P>0.05);治疗后6个月、12个月,放疗+替吉奥组患者的生存率均显著高于放疗+卡培他滨组(P<0.05)。结论调强放疗同步替吉奥治疗中老年食管癌的临床疗效和生存率优于调强放疗同步卡培他滨,且不良反应更少。Objective To compare the clinical efficacy of intensity modulated radiotherapy combined with chemotherapy of S-1 or capecitabine in the treatment of advanced esophageal cancer in middle-aged and elderly patients.Method The clinical data of 50 middleaged and elderly patients with advanced esophageal cancer admitted to Fuyang Cancer Hospital of Anhui Province from April 2017 to October 2020 were retrospectively analyzed.According to the different treatment methods,they were divided into intensity modulated radiotherapy combined with S-1 chemotherapy group(radiotherapy+S-1 group,25 cases)and intensity modulated radiotherapy combined with capecitabine chemotherapy group(radiotherapy+capecitabine group,25 cases).21 days was a cycle,and both groups were treated for two cycles.The clinical efficacy after treatment,the occurrence of adverse reactions 1 year after treatment and the survival at 4,6 and 12 months after treatment were compared and analyzed between the two groups.Result After treatment,the total remission rate in radiotherapy+S-1 group was significantly higher than that in radiotherapy+capecitabine group(P<0.05).One year after treatment,there was no significant difference in the incidence of bone marrow suppression and digestive tract adverse reactions between two groups(P>0.05).The incidence of peripheral neuritis,radioactive esophagitis and hand and foot skin injury in radiotherapy+S-1 group was significantly lower than that in radiotherapy+capecitabine group(P<0.05).4 months after treatment,there was no significant difference in survival rate between two groups(P>0.05);At 6 months and 12 months after treatment,the survival rates in radiotherapy+S-1 group were significantly higher than those in radiotherapy+capecitabine group(P<0.05).Conclusion The clinical efficacy and survival rate of intensity modulated radiotherapy combined with S-1 in the treatment of middle-aged and elderly esophageal cancer are better than intensity modulated radiotherapy combined with capecitabine,and there are fewer adverse reactio

关 键 词：中老年 晚期食管癌 调强放疗 替吉奥 卡培他滨 

分 类 号：R735.1[医药卫生—肿瘤]